Eyes On Trials

  ABC Pharmaceuticals, a pioneering biotech firm known for its cutting-edge research in therapeutic innovations. Amidst their quest for groundbreaking treatments, they encountered a pivotal juncture during a Phase IIb/III cardiovascular trial. Regulatory shifts, supply chain vulnerabilities, and safety concerns cast a shadow over their aspirations. This is the story of how the Clinical Project Manager, redefined risk management, embracing challenges as catalysts for innovation while transforming stakeholder conversations. ABC Pharmaceuticals, driven by innovation, harbored a risk-averse culture—prioritizing safety and efficacy without aggressively embracing uncertainties. CPM recognized the need for a paradigm shift. He envisioned risk not merely as a hurdle but as a potential driver of transformative change within the trial landscape. The Evolution of Risk Management: Identifying the Challenges: ABC Pharmaceuticals’ initial risk assessments identified potential disruptions:...

Potential Risks is an essential part because Clinical Trials projects tend to be time constrained, post huge technical challenges and suffer from adequate resources. Not all the risks are equally important, should focus on risks that can materially affect project objectives or uncertainty that matters. There are numbers of factors can be internal, such as available resources, skills level of human resources, funding availability, management approach, time constraints etc. Risks also vary depending on the stakeholder: subjects, study team, sponsor, competent authorities, target population and that is why stakeholders education, awareness, engagement and support are critical success factors for project risk management. Organizational and stakeholder risk attitudes and risk tolerances must be explicitly identified and managed before and during the project. Clinical Trials process may be divided into three main steps, each of these steps can be associated ...